The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Abstract Introduction Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody...
Main Authors: | Wen‐Qian Li, Han‐Fei Guo, Ling‐Yu Li, Yong‐Fei Zhang, Jiu‐Wei Cui |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-07-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.4052 |
Similar Items
-
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
by: Qing Wei, et al.
Published: (2024-01-01) -
Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation
by: Weiran Cao, et al.
Published: (2022-09-01) -
Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
by: Yu-Jie Wang, et al.
Published: (2017-01-01) -
Mechanisms of Resistance to Antibody–Drug Conjugates
by: Rachel Occhiogrosso Abelman, et al.
Published: (2023-02-01) -
Antibody–Drug Conjugates for the Treatment of Breast Cancer
by: Chiara Corti, et al.
Published: (2021-06-01)